By Karen Ivester, inSeption Group
Autologous cell therapy expertise and service providers are simultaneously in short supply and high demand. But the dynamic nature of inherently complex cell therapy-focused clinical trials requires individuals with a keen understanding of site and partner needs. Moreover, to fully take advantage of these individuals’ capabilities, responsive, high-touch coordination and a plan to communicate effectively across multiple stakeholders are necessary.
Such communication is critical to deliver the cross-functional, integrated clinical development activities necessary to decrease development time and to prevent and/or mitigate a myriad of risks. While clear, consistent communications are important to any clinical trial, the consequences of mistakes are exacerbated in autologous cell therapy clinical trials.
Plus, building a rapport with proficient sites is more difficult, since personnel with cell and gene therapy experience are highly sought-after and prone to moving around between organizations and projects.